Loading
institutionsInstitution
Sarcoma Oncology Center
The Sarcoma Oncology Center in Santa Monica, the practice of Sant Chawla, offers sarcoma second opinions, clinical trials and multimodal treatment planning.
Overview
The Sarcoma Oncology Center is a sarcoma-focused practice in Santa Monica, California, offering second opinions, access to clinical trials and multimodal treatment planning; its director Sant Chawla led the aldoxorubicin trials and co-founded Gemini Therapeutics. Patient-bookable.
Location
Santa Monica, US
Type
hospital
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#429 · 12 points (0 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Sarcoma Oncology Center, including child institutions. 36 works · 168 citations · 61% open access · 36% clinical trials · 0% reviews.
Oncology works per year
122022
12023
92024
42025
102026
Most works
- Sant P. Chawla22 works
- Erlinda M. Gordon15 works
- Neal Shiv Chawla11 works
- Ania Moradkhani8 works
- Samantha Jeffrey7 works
- Frederick L. Hall6 works
- Victoria S. Chua4 works
- Paul Y. Song4 works
- Victoria S. Chua-Alcala4 works
- Sant P. Chawla3 works
Most cited
Similar pages
- InstitutionDocrates Cancer Center
Shares Multidisciplinary tumour boards and the tag fcct-directory.
- CompanyPrivate Health Management
Shares Multidisciplinary tumour boards and the tag fcct-directory.
- CompanyPrivate Medical
Shares Multidisciplinary tumour boards and the tag fcct-directory.
- CompanyPathfinder Oncology
Shares Multidisciplinary tumour boards and the tag fcct-directory.
- InstitutionAsthra Health
Shares Multidisciplinary tumour boards and the tag fcct-directory.
- Key paperFirst-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial
Shares Aldoxorubicin, Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma.
- TargetSQSTM1
- CompanySARC (Sarcoma Alliance for Research through Collaboration)
cancers
technologies
drugs
Phase 3Albumin-binding small-molecule prodrug of doxorubicin, intravenous